Report Overview

The UK Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Chronic Inflammatory Demyelinating Polyneuritis (CIDP) is a rare autoimmune disorder wherein the body's immune system attacks the myelin causing various symptoms such as numbness, weakness, and a lack of certain reflexes.

CIDP is a rare disorder that can affect any age group and the onset of order may begin during the decade of life. It has been estimated that over 10 million people in the UK (adults and children) suffer from a neurological disorder that has a significant impact on their lives. CIDP affects males twice as often as females and the average age of onset is 50. The incidence (1.6/100,000/year) and prevalence (8.9/100,000) of CIDP have been shown in the UK.



Market Growth Drivers

The prevalence of CIDP has increased dramatically, paving the way for the growth of the UK market for CIDP. The increasing incidence of CIDP is a major concern in the medical sector, hence the major market growth driver as well. Therefore, the high unmet need for advanced treatment options for the disease is likely to bring to view new opportunities for market players over the forecast period.

Several public and private organizations launched initiatives for R&D activities that produced positive results in the market of CIDP. Remarkable results have been achieved through rigorous research and development efforts and clinical trials. Several new drugs are introduced following recent FDA approvals, which also spur the growth of the CIDP market. Other factors supporting the market growth comprise surging awareness of the disease and government endeavors on the same.

Market Restraints

On the downside, the high cost of intravenous immunoglobulin (IVIG) treatment and the side effects accompanied with its administration such as hypotension, nausea, lower back pain, flushing, chills, wheezing, etc. remain a hindrance to the growth of the market.